Larimar to kick off higher dose of lead rare disease drug, initiate OLE trial

The FDA gave Larimar Therapeutics the go-ahead to introduce a higher dose of its Friedreich’s ataxia treatment in a Phase II study.

The biotech announced Tuesday that the company can now use 50 mg doses of its lead drug, also known as CTI-1601, in the study. The 12 to 15 adult patients Larimar plans to enroll in that cohort will be randomized to either the drug or placebo, then dosed every day for the first two weeks.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

Beyond BCMA-Directed CAR T-Cell Therapy

Although survival rates for patients with multiple myeloma are improving, with a 5-year rate of about 60%, many patients relapse after treatment. “Patients have seen

June 22, 2024

UK’s life sciences sector sees $1.1B drop in foreign investments from 2021 to 2022

The UK’s pharma industry group is warning of a dire situation for the country’s life sciences sector, which saw a $1.1 billion (£0.9 billion) reduction

July 15, 2023

The role of emotion regulation in predicting suicidal risk in depressed individuals

Depressed individuals who reflexively attempt to dampen their initial emotional responses to reminders of their negative memories have a low tolerance for distressing emotional stimuli

November 26, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.